Physician profile
Omar Mulla Ossmann
NPI 1396779435
$13,427.73
in general payments reported to CMS, 2019-2025
53 companies · $1,199 in 2025
The $1,199 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $1,933 · 2021: $3,241 · 2022: $2,822 · 2023: $1,552 · 2024: $1,474 · 2025: $1,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,184 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,183.83 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,322.27 | 2021-2025 | |
| Mdd US Operations, LLC | $1,144.92 | 2022-2025 | Gocovri, Gocovri, Apokyn |
| Supernus Pharmaceuticals, INC. | $1,033.57 | 2019-2025 | Qelbree |
| Biogen, INC. | $949.55 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Novartis Pharmaceuticals Corporation | $751.95 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $641.00 | 2019-2022 | |
| Genzyme Corporation | $533.69 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $492.52 | 2019-2025 | Lyvispah, Rytary, Crexont |
| Lilly USA, LLC | $462.46 | 2021-2024 | Emgality, Reyvow, Amyvid |
| Acadia Pharmaceuticals INC | $382.80 | 2019-2025 | Nuplazid |
| Biohaven Pharmaceuticals, INC. | $363.45 | 2021 | |
| Sk Life Science, INC. | $329.31 | 2020-2025 | |
| Amgen INC. | $309.80 | 2019-2024 | Aimovig, Uplizna |
| Pfizer INC. | $295.14 | 2021-2024 | |
| Ucb, INC. | $284.55 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Mulla Ossmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.